Trials / Completed
CompletedNCT00766857
Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure
The Effect of Exenatide Compared to Insulin Glargine on Cardiac Function and Metabolism in Type 2 Diabetic Patients With Congestive Heart Failure: a Randomized Comparator-controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Amsterdam UMC, location VUmc · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement of cardiac efficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | exenatide | Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks). |
| DRUG | Insulin glargine | Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance. |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2008-10-06
- Last updated
- 2015-12-09
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00766857. Inclusion in this directory is not an endorsement.